Anixa Biosciences, Inc. (ANIX) Stock

Anixa Biosciences, Inc. (ANIX) is a Healthcare stock trading at $2.91 (as of 2026-06-18), with a market capitalization of $84.49M and a trailing P/E of -8.2. Figures are sourced from first-party U.S. SEC EDGAR filings and market data.

Anixa Biosciences, Inc. is a biotechnology company developing therapies, vaccine candidates, and related immunotherapy approaches for oncology and infectious diseases. Its pipeline includes CAR-T technologies, antiviral drug candidates for COVID-19, and vaccines aimed at triple-negative breast cancer and ovarian cancer.

Valuation — source: SEC EDGAR (first-party)
Price	$2.91
Market Cap	$84.49M
P/E Ratio	-8.2
Price / Book	6.35
Price / Sales	400.18
DCF Value (model)	$-3.62
DCF Upside vs Price	-224.4%

Profitability & Growth — source: SEC EDGAR
Revenue (TTM)	$210000.00
Net Margin	-5978.1%
Return on Equity	-75.9%
Current Ratio	9.79
Revenue Growth (YoY)	-100.0%
EPS Growth (YoY)	21.9%
FCF Growth (YoY)	18.1%

Valuation vs Sector & Industry
Stock P/E	-8.2
Sector P/E (Healthcare)	20.9
Industry P/E (Pharmaceutical Products)	17.0
vs Sector	-139.4%
vs Industry	-148.4%

Smart-Money Activity — SEC Form 4 / 13F / Congressional disclosures
Top Institutional Holder	VANGUARD GROUP INC ($4.55M)
Institutional Holders Tracked	10

Company
Sector	Healthcare
Industry	Pharmaceutical Products
CEO	Amit Kumar
Employees	5
Country	US
IPO Date	1983-10-07

Related Companies (Business model: Biotech (Clinical / Commercial-Stage); 8 closest by market cap; US-domiciled)

Data as of 2026-06-18.

Figures sourced from U.S. Securities and Exchange Commission (SEC EDGAR) filings and market data. Not personalized investment advice.